GH Increase2-3x
Studies8
Participants1,286
StatusAvailable
Ipamorelin
Selective Growth Hormone Secretagogue (GHRP)
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that specifically stimulates the release of growth hormone without affecting other hormones. Unlike other GHRPs, Ipamorelin does not increase cortisol, acetylcholine, prolactin, or aldosterone levels, making it the most selective and well-tolerated growth hormone secretagogue available for research and therapeutic applications.
Clinical Safety Profile
Reported Side Effects
Mild injection site reactions
Temporary water retention
Slight increase in hunger (minimal)
Possible joint stiffness during adaptation
Mild fatigue during initial weeks
Occasional headache
Transient numbness in hands/feet
Side Effect Management (Clinical Trial Data)
Injection Site Reaction
Infrequent
8.7%
Mild Water Retention
Occasional
12.3%
Transient Fatigue
Infrequent
5.8%
Mild Headache
Infrequent
4.2%
Joint Stiffness
Infrequent
3.6%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status
CONTRAINDICATIONS
• Active cancer or history of malignancy
• Severe heart disease or heart failure
• Diabetic ketoacidosis
• Known hypersensitivity to growth hormone
Medical Disclaimer
Ipamorelin is currently in research phase and is not FDA-approved for human therapeutic use. This information is for educational purposes only and should not replace consultation with healthcare providers. Individual results may vary. Medical supervision is recommended for all research applications.